Co-Authors
This is a "connection" page, showing publications co-authored by SANKAR N MAITY and ANA APARICIO.
Connection Strength
1.041
-
Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011 Nov; 1(6):466-8.
Score: 0.421
-
Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol. 2018; 8:69.
Score: 0.164
-
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res. 2016 Mar 15; 22(6):1520-30.
Score: 0.139
-
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 01; 18(3):666-77.
Score: 0.106
-
EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. Biochim Biophys Acta Rev Cancer. 2018 12; 1870(2):229-238.
Score: 0.042
-
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep. 2017 02 21; 18(8):1970-1981.
Score: 0.038
-
Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 2016 03 03; 11(3):184-93.
Score: 0.035
-
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
Score: 0.034
-
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47.
Score: 0.031
-
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61.
Score: 0.030